UCB SA (OTCMKTS:UCBJF) Sees Large Increase in Short Interest

UCB SA (OTCMKTS:UCBJF - Get Free Report) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 643,700 shares, a growth of 59.5% from the October 31st total of 403,500 shares. Based on an average trading volume of 200 shares, the days-to-cover ratio is currently 3,218.5 days.

UCB Price Performance

UCB stock remained flat at $174.00 during midday trading on Friday. 124 shares of the company were exchanged, compared to its average volume of 317. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a 12 month low of $73.54 and a 12 month high of $194.76. The company's 50 day simple moving average is $180.94 and its 200 day simple moving average is $160.30.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.